Log In
Print this Print this

Leukeran, chlorambucil

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionNitrogen mustard-type DNA alkylating agent
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationChronic lymphocytic leukemia (CLL)
Indication DetailsPalliative treatment of chronic lymphocytic leukemia (CLL)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today